Airway Therapeutics

  • About Us
  • Pipeline
  • BPD
  • Respiratory & Inflammatory Diseases
  • News
  • Contact

Commentary: Pattern Recognition Proteins: First Line of Defense Against Coronaviruses

February 8, 2022 By Airway Therapeutics

Authors: Michael DePietro and Marc Salzberg, Airway Therapeutics, Marietta, GA, United States

A Commentary on
Pattern Recognition Proteins: First Line of Defense Against Coronaviruses
By Labarrere CA and Kassab GS (2021). Front. Immunol. 12:652252. doi: 10.3389/fimmu.2021.652252
Introduction
Labarrere and Kassab recently wrote an informative paper that includes a very interesting overview of the role Surfactant Protein D (SP-D) plays as part of the innate immune system in the defense against several viral pathogens including SARS-CoV-2 (1). It has been described that the Carbohydrate Recognition Domain (CRD) of SP-D recognizes and binds to carbohydrates present in certain viruses such as the hemagglutinin of Influenza A Virus (2, 3) or the Spike (S)-Protein of SARS-CoV and SARS-Cov-2 (4, 5). Binding promotes agglutination and clearance of the virus (6). Additionally, SP-D modulates the inflammatory response induced by pathogens, SP-D interacts with specific receptors on the inflammatory cells such as the TLR4 complex, inhibiting the pro-inflammatory response induced by viruses (7–9).

Of particular interest given the SARS-CoV-2 pandemic, Labarrere and Kassab highlight several studies which have demonstrated a correlation of relatively high serum levels of SP-D with the development of severe COVID-19 pneumonia (10, 11). These findings suggest a role of Surfactant Protein D as a marker of disease severity as well as a potential therapeutic agent which Labarrere and Kassab discuss.

We would like to point out that in addition to high levels of serum levels being associated with COVID-19 severity, low levels of SP-D in the lung as measured in bronchoalveolar lavage fluid (BALF) have been reported in severe COVID-19 (5) and have been associated with an increased risk of the acute respiratory distress syndrome (ARDS) (12). These observations resulted in the filing of a New Investigational Drug (IND) application for a recombinant human surfactant Protein D (rhSP-D) formulation administered as a therapeutic agent for patients with severe COVID-19 with respiratory failure, as well as the initiation of a Phase 1B study this therapy, that is currently enrolling patients (NCT 04659122 http://www.ClinicalTrials.gov).

 

Read the full article here: Frontiers | Commentary: Pattern Recognition Proteins: First Line of Defense Against Coronaviruses | Immunology (frontiersin.org)

Filed Under: Scientific Publications

logo

Airway Therapeutics, Inc

1200 Johnson Ferry Rd, Suite 300
Marietta, GA 30068

513.770.9630

  • Privacy

Sitemap

  • Home
  • About Us
  • Pipeline
  • BPD
  • Respiratory & Inflammatory Diseases
  • News
  • Contact
Copyright © 2015 Airway Therapeutics, Inc. All Rights Reserved.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.
Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT
MENU
  • About Us
  • Pipeline
  • BPD
  • Respiratory & Inflammatory Diseases
  • News
  • Contact